Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash & Equivalents (2020 - 2023)

Candel Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $43.0 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 44.31% year-over-year to $43.0 million; the TTM value through Sep 2023 reached $43.0 million, down 44.31%, while the annual FY2022 figure was $70.1 million, 15.23% down from the prior year.
  • Cash & Equivalents for Q3 2023 was $43.0 million at Candel Therapeutics, down from $51.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $94.3 million in Q1 2022 and bottomed at $24.3 million in Q2 2021.
  • The 4-year median for Cash & Equivalents is $70.1 million (2022), against an average of $64.8 million.
  • The largest annual shift saw Cash & Equivalents surged 256.89% in 2022 before it crashed 44.31% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $35.1 million in 2020, then surged by 135.76% to $82.6 million in 2021, then decreased by 15.23% to $70.1 million in 2022, then tumbled by 38.65% to $43.0 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Cash & Equivalents are $43.0 million (Q3 2023), $51.9 million (Q2 2023), and $59.3 million (Q1 2023).